Moscow [Russia], July 28 (ANI/Izvestia): Russian scientists have created a microfluidic platform that replicates blood flow in the brain. It is capable of supporting the vital activity of glioblastoma cells, one of the most aggressive forms of brain cancer that is difficult to treat.

The researchers found that the device, when exposed to red light, stimulates the activity of ion channels in cells and enhances the penetration of temozolomide, one of the main drugs for treating this tumour, into them. "Ion channels work like pumps -- they pull molecules into the cell. Temozolomide needs to get into the nucleus to destroy the cancer cell. Red light increases the opening and closing of channels, the concentration of the drug in the cell grows faster, and the cell dies. In the experiments, we managed to destroy up to 95-98 per cent of glioblastoma cells -- this is five times more than in control samples without stimulation," the head of the study, Associate Professor of the Institute of Bionic Technologies and Engineering Alexander Markov told Izvestia.

Also Read | Earthquake in Pakistan: Quake of Magnitude 4.0 on Richter Scale Hits Region, No Casualties Reported.

In the future, the researchers want to use the platform to select hybrid therapy for other forms of cancer.

Scientists from the Institute of Bionic Technologies and Engineering worked on the creation of the microfluidic platform together with the experimental biotherapy group of the Institute of Regenerative Medicine of Sechenov University. (ANI/Izvestia)

Also Read | North Korean Leader Kim Jong-Un's Sister Kim Yo-Jong Says Not Interested in Any Proposal From Seoul, Won't Sit Down for Dialogue.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)